Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Hackensack Meridian Health Clear all
Terminated Phase 1Phase 2 Interventional

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

NCT04150965
View directory record Official record
Conditions
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
Interventions
Elotuzumab, pomalidomide, dexamethasone, Anti-LAG-3, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-TIGIT, Anti-TIGIT + Pomalidimide + Dexamethasone
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 1, 2026, 7:49 PM EDT
Recruiting Not applicable Interventional

Emotional Awareness Therapy Study

NCT07624825
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
TREAT-A, TREAT-B
Behavioral
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 1, 2026, 7:49 PM EDT
Not yet recruiting Phase 3 Interventional

Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant

NCT07621796
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Intravenous tenecteplase (TNK), Placebo
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 1, 2026, 7:49 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers

NCT05121766
View directory record Official record
Conditions
COVID-19
Interventions
Omega-3 (EPA+DHA), Placebo
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 1, 2026, 7:49 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

NCT04459416
View directory record Official record
Conditions
Multiple Myeloma, Hodgkin Disease, Non-Hodgkin Lymphoma
Interventions
Acupuncture, opioid, Assessments
Other · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 1, 2026, 7:49 PM EDT
Suspended Phase 1Phase 2 Interventional

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

NCT05199311
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Iberdomide, Oral Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 1, 2026, 7:49 PM EDT
Recruiting Not applicable Interventional

Actívatexto: Advancing Smoking Cessation and Physical Activity Among Latinos

NCT06926608
View directory record Official record
Conditions
Smoking, Smoking Cessation, Physical Inactivity
Interventions
Actívatexto, Decídetexto
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 1, 2026, 7:49 PM EDT
Terminated Not applicable Interventional Results available

Effectiveness of Using Educational Modules Via Bedside Tablet in Newly Diagnosed Type 1 Diabetes

NCT03534193
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Molly Center Diabetes Care Guide (Paper-based), Tablet based interactive diabetes education modules
Other
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
Up to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 1, 2026, 7:49 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

NCT02446236
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Lenalidomide, Ibrutinib, Rituximab
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 1, 2026, 7:49 PM EDT
Completed No phase listed Observational

Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19

NCT04343898
View directory record Official record
Conditions
Coronavirus Infection
Interventions
No intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
5,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 1, 2026, 7:49 PM EDT
Recruiting Not applicable Interventional

Support for Cancer Patients Awaiting News

NCT06199570
View directory record Official record
Conditions
Lung Cancer
Interventions
Adapted Stress Management Program, Enhanced Usual Care
Behavioral
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 1, 2026, 7:49 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

NCT04700176
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Pomalidomide, All-trans retinoic acid, Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 1, 2026, 7:49 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft

NCT04263025
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cryopreserved Umbilical Cord Allograft, Robot-Assisted Radical Prostatectomy
Biological · Procedure
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
30 Years to 70 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 1, 2026, 7:49 PM EDT
Terminated Not applicable Interventional Results available

Music Therapy Advocacy Recording Intervention (MTAR) on Internalized Stigma

NCT05723328
View directory record Official record
Conditions
Mental Health Issues, Bipolar Disorder, Depressive, Schizophrenia Spectrum and Other Psychotic Disorders, Anxiety Disorder
Interventions
Group Music Therapy Advocacy Recording Intervention (MTAR)
Behavioral
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Belle Mead, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 1, 2026, 7:49 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

NCT04091750
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab, Cabozantinib
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 1, 2026, 7:49 PM EDT
Completed Phase 3 Interventional Results available

Stem Cell Transplantation for Sickle Cell Anemia

NCT01877837
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, Fludarabine, Melphalan, Stem Cells
Drug · Procedure
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
2 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Sep 1, 2026, 7:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Childhood Obesity Programming by Intrauterine Growth Restriction

NCT03402139
View directory record Official record
Conditions
Childhood Obesity, Epigenetics
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
1 Hour to 24 Months
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 1, 2026, 7:49 PM EDT
Terminated Early Phase 1 Interventional Results available

Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study

NCT05096884
View directory record Official record
Conditions
Tachycardia, Dyspnea, COVID-19
Interventions
Metoprolol Succinate
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 1, 2026, 7:49 PM EDT
Not listed Phase 4 Interventional

MYnd Analytics Directed Therapy in Depression

NCT03328052
View directory record Official record
Conditions
Depression
Interventions
MYnd Analytics PEER Online directed antidepressant therapy, Conventional antidepressant therapy
Device · Other
Lead sponsor
Cota Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Brick, New Jersey • Hackensack, New Jersey • Holmdel, New Jersey + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 1, 2026, 7:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

DECIDE: Developing Tools for Lung Cancer Screening Discussion Improvement

NCT03891602
View directory record Official record
Conditions
Smoking, Smoking, Tobacco, Smoking, Cigarette, Lung Cancer
Interventions
Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale), Patient Trust in the Medical, Decision Conflict Scale (DCS) - Lung Cancer Screening, Shared Decision Making Questionnaire (SDM-Q)- Patient, Stage of Readiness for Smoking Cessation - Contemplation Ladder, Primary Care Clinicians' Lung Cancer Screening Survey
Behavioral
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 80 Years
Enrollment
654 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 1, 2026, 7:49 PM EDT
Recruiting Phase 2 Interventional

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

NCT05715229
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 1, 2026, 7:49 PM EDT
Completed No phase listed Observational Results available

A Prospective "Universal" Observational Database for COVID-19

NCT04347993
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
Not listed
Enrollment
4,588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 1, 2026, 7:49 PM EDT
Not yet recruiting Not applicable Interventional

Battlefield Acupressure for Acute Back Pain Management in the Emergency Department

NCT07771686
View directory record Official record
Conditions
Acute Back Pain
Interventions
Battlefield auricular acupressure, Sham
Procedure
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 1, 2026, 7:49 PM EDT
Terminated No phase listed Observational Results available

Fluoroquinolone Resistance Prevalence Study

NCT05824689
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 1, 2026, 7:49 PM EDT